Treating sickle cell anaemia: the TWiTCH trial

The TWiTCH study had a 1-2 year treatment period with extensive monitoring under trial conditions when the period of greatest risk after abnormal transcranial doppler (TCD) flow velocity diagnosis remains unknown and might be greater if the transfusion period is short.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-09, Vol.388 (10048), p.960-961
Main Authors: Gwam, Maureen, Nwosu, Carol
Format: Article
Language:English
Subjects:
Anemia, Sickle Cell - therapy
Blood transfusions
Clinical trials
Humans
Internal Medicine
Medical treatment
Patients
Sickle cell anemia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The TWiTCH study had a 1-2 year treatment period with extensive monitoring under trial conditions when the period of greatest risk after abnormal transcranial doppler (TCD) flow velocity diagnosis remains unknown and might be greater if the transfusion period is short.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(16)31493-3